Infant Bacterial Therapeutics AB (publ)
STO: IBT-B.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Staffan Stromberg
- Employees
- 8
- Headquarters
- Stockholm, Sweden
- IPO year
- 2016
- Market cap
- SEK 706.9M
- Website
- https://www.ibtherapeutics.com
Loading IBT-B…
Loading profile data…Frequently asked questions about IBT-B
What does Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) do?
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing I...
Where does IBT-B.ST trade?
Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) trades on the Stockholm Stock Exchange.
What sector is IBT-B.ST in?
Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Infant Bacterial Therapeutics AB (publ)?
Staffan Stromberg is the chief executive officer of Infant Bacterial Therapeutics AB (publ) (IBT-B.ST).
Where is Infant Bacterial Therapeutics AB (publ) headquartered?
Infant Bacterial Therapeutics AB (publ) is headquartered in Sweden.
Does IBT-B.ST pay a dividend?
Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IBT-B.ST go public?
Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) completed its initial public offering in 2016.